Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas.

abstract：:The antitumor effect and tumor levels of 5-fluoro-2'-deoxyuridylate (FdUMP) following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate (TT-62) were compared with those attained following intravenous (i.v.) or intraperitoneal (i.p.) administration of 5-fluorouracil (5-FU) or 5-fluoro-2'-deoxyuridine (FU...

journal_title：Anti-cancer drugs

authors： Nakajima Y,Iigo M,Hoshi A

更新日期：1992-06-01 00:00:00

abstract：:5-Fluorouracil (5-FU) is the most widely used agent for the management of colorectal cancer. Capecitabine is metabolized by three enzymatic actions, the last of which is mediated by thymidine phosphorylase, to produce 5-FU. Given the oral bioavailability of capecitabine as well as in-vitro and in-vivo findings showing...

journal_title：Anti-cancer drugs

authors： Patel PA

更新日期：2011-04-01 00:00:00

abstract：:The delivery formulation 5-FU-MS [5-fluorouracil (5-FU) incorporated in microspheres composed of a poly(glycolide-co-lactide) matrix] slowly releases 5-FU over 3 weeks. 5-FU-MS delivers higher concentrations of the drug to the i.p. tissues for a longer period of time with lower blood plasma concentrations than does an...

journal_title：Anti-cancer drugs

authors： Hagiwara A,Sakakura C,Shirasu M,Yamasaki J,Togawa T,Takahashi T,Muranishi S,Hyon S,Ikada Y

更新日期：1998-03-01 00:00:00

abstract：:Previously, we synthesized a series of hydrazide class of compounds and examined their cytotoxicity in a number of cancer cell lines. Among these analogues, SC144 exhibited potent cytotoxicity against a panel of drug-sensitive and drug-resistant cancer cell lines. To further explore its therapeutic potentials in the c...

journal_title：Anti-cancer drugs

authors： Oshima T,Cao X,Grande F,Yamada R,Garofalo A,Louie S,Neamati N

更新日期：2009-06-01 00:00:00

abstract：:In this study, we investigated the molecular mechanism of doxorubicin (dxr)-induced cytotoxicity on Jurkat cells - a model cell of human acute lymphoblastic leukemia - under normoxic (20% O2) and hypoxic (5% O2) conditions. Using in-cell western analysis, immunofluorescence, flow cytometry analysis, and biochemical in...

journal_title：Anti-cancer drugs

authors： Mendivil-Perez M,Velez-Pardo C,Jimenez-Del-Rio M

更新日期：2015-07-01 00:00:00

abstract：:The current reference treatment of hormone-refractory prostate cancer consists mainly of chemotherapy with docetaxel. To improve the management of advanced prostate cancer, one should examine the benefits of adding other agents to docetaxel. We examined the growth inhibitory effects of a triple combination, including ...

journal_title：Anti-cancer drugs

authors： Fischel JL,Ciccolini J,Formento P,Ferrero JM,Milano G

更新日期：2006-08-01 00:00:00

abstract：:Our objective was to clarify the efficacy of UFT administration after the complete resection of non-small cell lung cancer (NSCLC) at a single-center institution, avoiding the biases produced by interinstitutional differences. A total of 30 patients who underwent the complete resection of NSCLC at our hospital between...

journal_title：Anti-cancer drugs

authors： Ueda H,Sakada T,Kuwahara M,Motohiro A

更新日期：2004-01-01 00:00:00

abstract：:Para-toluenesulfonamide (PTS) has been implicated with anticancer effects against a variety of tumors. In the present study, we investigated the inhibitory effects of PTS on tongue squamous cell carcinoma (Tca-8113) and explored the lysosomal and mitochondrial changes after PTS treatment in vitro. High-performance liq...

journal_title：Anti-cancer drugs

authors： Liu Z,Liang C,Zhang Z,Pan J,Xia H,Zhong N,Li L

更新日期：2015-11-01 00:00:00

abstract：:A phase II trial was performed to determine the efficacy and tolerance of docetaxel plus oxaliplatin with hematopoietic growth factor support in previously untreated patients with advanced gastroesophageal adenocarcinoma. Thirty-five patients were entered in this trial. Treatment consisted of 3-weekly docetaxel 80 mg/...

journal_title：Anti-cancer drugs

authors： Hejna M,Raderer M,Zacherl J,Ba-Ssalamah A,Püspök A,Schmidinger M,Pluschnig U,Brodowicz T,Zielinski CC

更新日期：2008-06-01 00:00:00

abstract：:Aurora-B kinase overexpression plays important roles in the malignant progression of prostate cancer (PCa). AZD1152-HQPA, as an inhibitor of Aurora-B, has recently emerged as a promising agent for cancer treatment. In this study, we aimed to investigate the effects of AZD1152-HQPA on reactive oxygen species (ROS) gene...

journal_title：Anti-cancer drugs

authors： Zekri A,Mesbahi Y,Ghanizadeh-Vesali S,Alimoghaddam K,Ghavamzadeh A,Ghaffari SH

更新日期：2017-09-01 00:00:00

abstract：:The main aim of this study is to assess the safety and antitumor efficacy of a palladium(II) (Pd)-saccharinate complex with terpyridine. To characterize the Pd(II) complex in vitro, its cytotoxicity was evaluated using a water-soluble tetrazolium salt cell viability assay and the mechanism of cell death was assessed b...

journal_title：Anti-cancer drugs

authors： Cetin Y,Adiguzel Z,Polat HU,Akkoc T,Tas A,Cevatemre B,Celik G,Carikci B,Yilmaz VT,Ulukaya E,Acilan C

更新日期：2017-09-01 00:00:00

abstract：:Compounds that could block tumor angiogenesis and induce tumor cell differentiation in malignant gliomas represent a very valuable tool in anticancer treatments. In this paper, we demonstrate that more selective drugs, which interfere with specific cellular targets, could treat glioma more effectively. 8-Cl-cAMP and t...

journal_title：Anti-cancer drugs

authors： Drabek K,Pesić M,Piperski V,Ruzdijić S,Medić-Mijacević L,Pietrzkowski Z,Rakić L

更新日期：2000-10-01 00:00:00

abstract：:In melanoma, the RAS/RAF/MEK/ERK pathway is frequently activated by mutations in BRAF and NRAS. Selumetinib (AZD6244) is an oral, selective, non-ATP-competitive inhibitor of MEK1/2. Here, we describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation. She is currently being treated with selumetin...

journal_title：Anti-cancer drugs

authors： Boers-Sonderen MJ,Desar IM,Blokx W,Timmer-Bonte JN,van Herpen CM

更新日期：2012-08-01 00:00:00

abstract：:Studies have shown that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells. However, breast cancer cells are generally resistant to TRAIL. In the present study, we explored the effect of bufalin on TRAIL-induced breast cancer cell apoptosis. The results showed...

journal_title：Anti-cancer drugs

authors： Yan S,Qu X,Xu L,Che X,Ma Y,Zhang L,Teng Y,Zou H,Liu Y

更新日期：2014-07-01 00:00:00

abstract：:Zoledronic acid has been the standard of care for the prevention of skeletal-related events in patients with bone metastases from prostate cancer for the past 10 years. However, its potent antitumor activity has been questioned. We report the occurrence of a complete clinical and biological response to zoledronic acid...

journal_title：Anti-cancer drugs

authors： Pouessel D,Culine S

更新日期：2012-01-01 00:00:00

abstract：:Tumor-to-tumor metastasis is a rare phenomenon, with around 150 cases being reported in the literature. Breast cancer is the second most commonly reported donor tumor after lung cancer, but thymic epithelial tumors have never been reported as recipient tumors. Furthermore, the thymus is rarely affected by metastases. ...

journal_title：Anti-cancer drugs

authors： Moretto R,Cella CA,Raimondo L,Formisano L,Nappi L,Rescigno P,Buonerba C,Calabrese F,Ottaviano M,Di Lorenzo G,Matano E,Damiano V,Palmieri G

更新日期：2013-08-01 00:00:00

abstract：:Hemolytic uremic syndrome (HUS) is a rare clinical and biological entity. HUS has been reported after several anticancer chemotherapies and most often after mitomycin C-based chemotherapy regimens. Little information is available concerning the occurrence and outcome of this syndrome after administration of more recen...

journal_title：Anti-cancer drugs

authors： Gross M,Hiesse C,Kriaa F,Goldwasser F

更新日期：1999-07-01 00:00:00

abstract：:beta-Lapachone is a naturally occurring quinone obtained from the bark of the lapacho tree (Tabebuia avellanedae) with cancer chemopreventive properties. The objective of the present study was to investigate the effect of beta-lapachone on the cell growth and apoptosis in human colon carcinoma tumor cell line HCT-116....

journal_title：Anti-cancer drugs

authors： Choi BT,Cheong J,Choi YH

更新日期：2003-11-01 00:00:00

abstract：:To devise a meaningful nutritional therapy in cancer, a greater understanding of nutritional dimensions as well as of expectations of patients and disease impact is essential. We have shown that nutritional deterioration in patients with gastrointestinal and head and neck cancer was multifactorial and mainly determine...

journal_title：Anti-cancer drugs

authors： Ravasco P

更新日期：2011-08-01 00:00:00

abstract：:Renal cell carcinoma (RCC) is one of the most frequent malignancies of the adults. Its incidence has been increasing steadily by 2-4% each year. Up to 30% of patients present with metastases at diagnosis. It is a highly vascularized cancer because of the hypoxia-induced factor stabilization as a consequence of von Hip...

journal_title：Anti-cancer drugs

authors： Nigro O,Pastore A,Tartaro T,Bolzacchini E,Tuzi A,Pinotti G

更新日期：2019-04-01 00:00:00

abstract：:Although baseline plasma homocysteine levels are related to pemetrexed toxicities in patients treated without folate supplementation, the relationship between these parameters in patients treated with folate supplementation is not well understood. The pretreatment plasma homocysteine levels were measured in non-small-...

journal_title：Anti-cancer drugs

authors： Tanaka H,Horiike A,Sakatani T,Saito R,Yanagitani N,Kudo K,Ohyanagi F,Horai T,Nishio M

更新日期：2015-06-01 00:00:00

abstract：:The array of tools currently available and the aim of treatment make choosing the best therapeutic strategy in metastatic colorectal cancer (CRC) an increasing challenge worldwide. We present the case of a 53-year-old man with metachronous metastases (liver-only metastatic disease) treated with FOLFOXIRI as first-line...

journal_title：Anti-cancer drugs

authors： Rizzo A,Palloni A,Frega G,Abbati F,De Lorenzo S,Brocchi S,Brandi G

更新日期：2019-04-01 00:00:00

abstract：:Cancer stem cells play a fundamental role in the growth, metastasis, recurrence, and chemoresistance of cancers of various origins; therefore, targeting these cells may prospectively help to eradicate cancer cells from patients. In this study, the effect of tetrandrine on the proliferation of CD133-positive (CD133) He...

journal_title：Anti-cancer drugs

authors： Cui X,Xiao D,Wang X

更新日期：2019-10-01 00:00:00

abstract：:This study aimed to further the understanding of the incidence of adverse events (AEs) in a population-based representative liver cancer population where there is currently a lack of knowledge. We carried out a retrospective cohort study using data from an administrative claims database between 1 January 2004 and 31 D...

journal_title：Anti-cancer drugs

authors： Dreyfus B,Kawabata HM,Gomez-Caminero A

更新日期：2013-07-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) is the world's leading cause of cancer death and about 75% of all patients have advanced disease incurable with localized treatments (surgery and radiotherapy) alone. The aims of therapy in these are palliation of symptoms and extension of life. A substantial body of evidence has eme...

journal_title：Anti-cancer drugs

authors： Nicum S,Cullen MH

更新日期：2000-09-01 00:00:00

abstract：:Neuroblastoma is one of the most common cancers in infancy, arising from the neuroblasts during embryonic development. This cancer is difficult to treat and resistance to chemotherapy is often found; therefore, clinical trials of novel therapeutic approaches, such as targeted-cancer signaling, could be an alternative ...

journal_title：Anti-cancer drugs

authors： Suebsoonthron J,Jaroonwitchawan T,Yamabhai M,Noisa P

更新日期：2017-06-01 00:00:00

abstract：:Leucine-rich repeat containing G protein-coupled receptor 5 (Lgr5) is a colorectal cancer (CRC) stem cell marker. The role of Lgr5-expressing stem cells in resistance to chemotherapy is controversial. The notion that Lgr5-expressing cells are more chemotherapy resistant is supported by some data; other data do not sup...

journal_title：Anti-cancer drugs

authors： Planutis AK,Holcombe RF,Planoutene MV,Planoutis KS

更新日期：2015-10-01 00:00:00

abstract：:To investigate the apoptotic mechanism of triple-negative breast cancer (TNBC) cells induced by gefitinib and PI3K inhibitor SF1126. MDA-MB-231, MDA-MB-436, and MCF-7 cells were incubated with 0.1 μmol/l gefitinib, 1 μmol/l gefitinib, 10 μmol/l gefitinib, 1 μmol/l SF1126, 0.1 μmol/l gefitinib+1 μmol/l SF1126, 1 μmol/l...

journal_title：Anti-cancer drugs

authors： Deng M,Wang J,Chen Y,Zhang L,Liu D

更新日期：2015-04-01 00:00:00

abstract：:Chemically modified tetracycline 3 (CMT-3) is a potential anticancer drug because of its retained matrix metalloproteinases inhibitory property. In the present study,we showed that CMT-3 significantly inhibited the growth and proliferation of human hepatocellular carcinoma HepG2 cells. Novel mechanisms including incre...

journal_title：Anti-cancer drugs

authors： Zhao L,Xu J,Jiao Y,Wang H,Fan S

更新日期：2014-11-01 00:00:00

abstract：:Over the past decade a number of vascular complications have emerged, such as newly developed or worsened hypertension, in patients who were administered with new cancer treatments for several types of cancer that were untreatable earlier. Hypertension is emerging as one of the most common adverse effects of therapy w...

journal_title：Anti-cancer drugs

authors： Aparicio-Gallego G,Afonso-Afonso FJ,León-Mateos L,Fírvida-Pérez JL,Vázquez-Estévez S,Lázaro-Quintela M,Ramos-Vázquez M,Fernández-Calvo O,Campos-Balea B,Antón-Aparicio LM

更新日期：2011-01-01 00:00:00